Molecular Pathology of Gallbladder Cancer
|
Molecular Pathology of Gallbladder Cancer |
About Contact |
| Home | • | Compounds | • | Expert Opinion | • | Trial Analysis | • | Pathways | • | Diseases | • | Workspace | • | TOUR |
 |
|
| Welcome to CuraBase® - The Curated and Collaborative Cancer Database Click Here to Learn More about CuraBase® |
|
Access to CuraBase® is free-of-charge for users in Academia or Non-Profit Organizations. |
|
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KRAS | Ras Signal Transduction Pathway |
20% | ||||||||||
| p16 | 31% | |||||||||||
| p53 | p53 Tumor Suppressor Pathway |
36% | ||||||||||
| Pi3-kinase | PI3-Kinase Signaling |
Gallbladder Carcinomas | 4% |
| CANCER.GOV PDQ® - Standard Treatments for Gallbladder Cancer | ||
